Eli Lilly's Experimental Weight-Loss Drug Shows Dramatic Results in Trial
Eli Lilly's new experimental weight-loss drug has successfully cleared a late-stage trial, demonstrating significant body weight reduction of up to 28%. These results are being compared to the effectiveness of bariatric surgery.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (75/100)Sources
Experimental Drug Yields Dramatic Weight Loss
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
By Gina Kolata and Rebecca Robbins
Read full article →Lilly’s Experimental Shot Cuts Body Weight by 28% in Study - Bloomberg.com
Lilly’s Experimental Shot Cuts Body Weight by 28% in Study Bloomberg.com
Read full article →New weight-loss shot appears to outperform other obesity drugs on market
Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday. The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss o...
By Maya Yang
Read full article →Eli Lilly says next-generation weight loss drug clears crucial obesity trial
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
Read full article →Lilly’s new experimental shot produced 28% weight loss
The injection is different than Zepbound and Foundayo.
By Jaimy Lee
Read full article →Lilly's triple agonist causes up to 28% of weight loss in late-stage trial
Read full article →Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, retatrutide, which delivered weight-loss results on par with those of bariatric surgery. In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved meaningful weight loss across all tested doses after 80 weeks: 12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight. 9 mg dose: aver...
By Tyler Durden
Read full article →
